Loading...
Loading...
FUSN| Name | Value |
|---|---|
| Revenues | 33.6M |
| Cost of Revenue | 0.4M |
| Gross Profit | 33.3M |
| Operating Expense | 27.9M |
| Operating I/L | -28.3M |
| Other Income/Expense | 1.4M |
| Interest Income | 2.3M |
| Pretax | -26.9M |
| Income Tax Expense | 1.3M |
| Net Income/Loss | -28.2M |
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company specializing in developing radiopharmaceuticals as precision medicines. The company's Targeted Alpha Therapies platform, combined with its proprietary Fast-Clear linker technology, enables the selective delivery of alpha particle payloads to tumors. Its lead product candidate, FPI-1434, is in Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Fusion Pharmaceuticals is also conducting preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to assess anti-tumor activity. Additionally, the company is progressing its earlier-stage product candidate, FPI-1966, into clinical development for the treatment of head and neck and bladder cancers expressing fibroblast growth factor receptor.
